M.D. Sass Investors Services Inc. purchased a new position in shares of Charles River Laboratories Intl. Inc (NYSE:CRL) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 46,380 shares of the medical research company’s stock, valued at approximately $6,582,000. Charles River Laboratories Intl. makes up 1.5% of M.D. Sass Investors Services Inc.’s holdings, making the stock its 26th largest holding.

A number of other institutional investors also recently added to or reduced their stakes in the business. Bank of New York Mellon Corp raised its holdings in shares of Charles River Laboratories Intl. by 49.4% in the second quarter. Bank of New York Mellon Corp now owns 978,183 shares of the medical research company’s stock worth $138,804,000 after acquiring an additional 323,625 shares during the last quarter. AQR Capital Management LLC lifted its position in shares of Charles River Laboratories Intl. by 18.0% in the first quarter. AQR Capital Management LLC now owns 2,082,761 shares of the medical research company’s stock valued at $301,042,000 after acquiring an additional 317,001 shares in the last quarter. OZ Management LP acquired a new stake in shares of Charles River Laboratories Intl. during the first quarter valued at $44,308,000. DekaBank Deutsche Girozentrale boosted its stake in shares of Charles River Laboratories Intl. by 18,244.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 241,596 shares of the medical research company’s stock valued at $29,368,000 after acquiring an additional 240,279 shares during the last quarter. Finally, King Luther Capital Management Corp boosted its stake in shares of Charles River Laboratories Intl. by 179.0% during the second quarter. King Luther Capital Management Corp now owns 343,777 shares of the medical research company’s stock valued at $48,782,000 after acquiring an additional 220,562 shares during the last quarter. 94.40% of the stock is owned by institutional investors.

In other Charles River Laboratories Intl. news, insider David Ross Smith sold 1,249 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $130.36, for a total value of $162,819.64. Following the sale, the insider now directly owns 19,327 shares of the company’s stock, valued at approximately $2,519,467.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.80% of the stock is currently owned by company insiders.

Shares of CRL stock traded up $0.63 during mid-day trading on Wednesday, hitting $130.31. 18,952 shares of the company’s stock were exchanged, compared to its average volume of 233,653. The stock has a market cap of $6.35 billion, a price-to-earnings ratio of 21.62, a PEG ratio of 1.66 and a beta of 1.09. The company has a quick ratio of 1.38, a current ratio of 1.59 and a debt-to-equity ratio of 1.47. Charles River Laboratories Intl. Inc has a fifty-two week low of $103.00 and a fifty-two week high of $149.07. The stock has a 50-day simple moving average of $132.09 and a two-hundred day simple moving average of $136.35.

Charles River Laboratories Intl. (NYSE:CRL) last released its earnings results on Wednesday, July 31st. The medical research company reported $1.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.55 by $0.08. The firm had revenue of $657.60 million during the quarter, compared to analyst estimates of $662.61 million. Charles River Laboratories Intl. had a return on equity of 22.01% and a net margin of 8.94%. The business’s quarterly revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.62 earnings per share. As a group, analysts anticipate that Charles River Laboratories Intl. Inc will post 6.52 earnings per share for the current fiscal year.

A number of analysts recently commented on CRL shares. ValuEngine cut Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. Leerink Swann assumed coverage on shares of Charles River Laboratories Intl. in a report on Monday, June 10th. They issued an “outperform” rating on the stock. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Svb Leerink began coverage on shares of Charles River Laboratories Intl. in a research note on Monday, June 10th. They set an “outperform” rating and a $155.00 price target on the stock. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $147.62.

Charles River Laboratories Intl. Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Conference Calls

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories Intl. Inc (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.